Company intelligence / Profile preview
Innospera Pharma Inc.
Montreal, Quebec, Canadainnospera.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Innospera’s lead drug candidate, ING‑006, targets IPF and has demonstrated superior potency to existing products in preclinical models. The company is preparing for clinical development and claims its approach offers an exceptional balance of safety and efficacy in targeting inflammatory and metabolic pathways. No human trial results have been reported yet.
- Therapeutic areas
- PulmonologyMetabolic Disorders
- Modalities
- Small moleculesSmall molecule GPCR modulators
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Investissement Québec, Seido Capital, Anges Québec provided $5M seed financing in May 2025
Beyond the preview
Go deeper on Innospera Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innospera Pharma Inc..